About Integral BioStrategy
Integral BioStrategy is partner-led by Ivan A. Valdez, PhD and Alfred Atallah, JD — pairing metabolic-science depth and translational judgment with biotech business and transaction-informed experience.
Partner-led scientific strategy
Integral BioStrategy is led by two partners who pair deep scientific interpretation with biotech business and transaction-informed judgment.
Co-founder
Ivan A. Valdez, PhD
Metabolic-disease science · islet & incretin biology · translational strategy
Ivan is a metabolic-disease scientist with more than 15 years in diabetes and islet biology. He earned his PhD at Harvard University / Joslin Diabetes Center in the laboratory of Rohit N. Kulkarni, with postdoctoral research alongside Ralph A. DeFronzo — work on the islet, beta-cell, and incretin mechanisms behind today’s metabolic therapies. He is first author of papers in Science Translational Medicine and Cell Reports, among ten peer-reviewed publications.
As a former healthcare-strategy consultant, he turned that depth into decision-ready strategy across 500+ physician, stakeholder, and expert interviews, dozens with key opinion leaders — reading what the data support, what a partner will challenge, and which experiment changes the answer.
He developed the patent-pending Islet Coordination Score, a framework that identifies subclinical kidney and liver disease in adults with normal glucose. His through-line is integration — connecting biology, evidence, and strategy across fields most people keep separate — and an advocacy for the patients a one-size story overlooks: from managing a number to preserving an organ.
Credentials
- PhD, Harvard University / Joslin Diabetes Center
- First-author publications in Science Translational Medicine and Cell Reports
- NIH (F31)– and American Diabetes Association–funded
- Developed the patent-pending Islet Coordination Score
Co-founder
Alfred Atallah, JD
Biopharma leadership · dealmaking · transactional law
Alfred is a biopharma executive and dealmaker with two decades of transactional law behind him. He currently leads an early-stage biopharma company as interim CEO and advises another, negotiating the partnerships, licensing, and financing — including cross-border deals with China — that turn science into a company.
At Integral BioStrategy, he makes sure the deal is as sound as the science: structured, negotiated, and protective of the value a team has built.
Credentials
- Interim CEO, early-stage biopharma company; advisor to another early-stage venture
- Two decades of transactional and business law — partnership, licensing, and deal negotiation; NDAs, letters of intent, entity formation
- JD, University of San Diego School of Law; Member, State Bar of California
Depth where it matters
Integral BioStrategy is grounded in diabetes, obesity, and metabolic disease — including incretin biology, islet and beta-cell function, glucagon biology, and translational metabolism — and brings mechanistic depth together with the strategic judgment to turn it into clear direction.
Engagements are partner-led. When a scoped question calls for it, Integral draws on an extended network of advisors and external experts — across clinical strategy, behavioral health, biomedical research, program leadership, and commercialization.
Specialized perspective, engaged by scope
A curated sample of a larger network, engaged by scope.
Clinical psychologist and digital health leader with experience in care-model design, behavioral health innovation, program development, patient engagement, outcomes frameworks, and behavior-change strategy.
Penn-trained neuroscientist, Harvard Medical School / Boston Children's research fellow, and Dean of Health Professions with experience in biomedical research, healthcare education, workforce training, and translational program leadership.
Harvard-trained cancer biology scientist with experience in biomedical research, STEM education, mentorship, program development, and scientific training. She currently serves as Associate Dean at Yale School of Medicine / Office of Collaborative Excellence.
Named advisors represent selected perspectives, not the full network. They are not automatically involved in every engagement, and contribute only when their perspective is relevant to a specific scoped engagement; when a question calls for it, Integral may engage additional external experts. Advisor participation is scoped separately and does not imply endorsement by or representation of any current employer or institution. Standard Integral BioStrategy engagements remain scientific and strategic advisory unless additional expertise is separately scoped in writing.
How engagements work
Integral BioStrategy works best when a team has a specific decision to pressure-test: what the biology supports, what the evidence shows, what remains uncertain, and what claim is defensible now. Every engagement begins with a confidential scoping conversation and a short written scope before work starts, so expectations, deliverables, and boundaries are clear from the outset.
Scoped
A brief scoping call, then a written scope defining the question, deliverable, and timeline before work begins.
Partner-led
Ivan and Alfred lead engagements directly. When a question calls for expertise beyond the core team, Integral may draw on a scoped network of advisors, mentors, colleagues, and external experts.
Confidential
Client information and findings are treated as confidential; deliverables are evidence-graded and decision-oriented.
For the full set of offerings and how engagements are scoped, see Services.
Have a scientific strategy question?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? [email protected]